The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics
 
Ghassan El-Haddad
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Bayer; Boston Scientific; Canon Medical System; Northstar Medical radioisotopes; Novartis; TERUMO
Patents, Royalties, Other Intellectual Property - Patent Title: Locking Brakes For Enteral Feeding Tube Retention Member Inventor: Ghassan Elias El-Haddad Patent number: 10,492,999 Issue Date: December 3, 2019 Assignee: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
 
Kenneth L. Gage
Employment - Blueberry Pediatrics (I)
 
Mikalai Budzevich
No Relationships to Disclose
 
Michael J Schell
No Relationships to Disclose
 
Eduardo G Moros
No Relationships to Disclose
 
Christopher Tichacek
No Relationships to Disclose
 
William R Gibbons
No Relationships to Disclose
 
Rebecca E Rogers
No Relationships to Disclose
 
Michael L Nickels
No Relationships to Disclose
 
Leticia Tetteh
No Relationships to Disclose
 
Zeynep Eroglu
Consulting or Advisory Role - Incyte; Pfizer; Regeneron; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Lilit Karapetyan
No Relationships to Disclose
 
Andrew Scott Brohl
Consulting or Advisory Role - Bayer; Deciphera
Expert Testimony - GlaxoSmithKline (I)
 
Joseph Markowitz
Stock and Other Ownership Interests - Aflac; Amdocs; Consolidated Edison; CVS; Intel
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Karen Hayes
Employment - Modulation Therapeutics
Leadership - Modulation Therapeutics
Stock and Other Ownership Interests - Modulation Therapeutics
Research Funding - Modulation Therapeutics
 
Lori Hazlehurst
Employment - Modulation Therapeutics; Modulation Therapeutics (I)
Leadership - Modulation Therapeutics; Modulation Therapeutics (I)
Stock and Other Ownership Interests - Modulation Therapeutics; Modulation Therapeutics (I)
Research Funding - Modulation Therapeutics; Modulation Therapeutics (I)
(OPTIONAL) Uncompensated Relationships - Modulation Therapeutics; Modulation Therapeutics (I)
 
Mark McLaughlin
Employment - Modulation Therapeutics
Leadership - Modulation Therapeutics
Stock and Other Ownership Interests - Modulation Therapeutics
Research Funding - Modulation Therapeutics
Patents, Royalties, Other Intellectual Property - Modulation Therapeutics
(OPTIONAL) Uncompensated Relationships - Modulation Therapeutics
 
David L Morse
Patents, Royalties, Other Intellectual Property - Modulation Therapeutics